The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in the phase 3 ATOMIC trial. “These data established this combination as a new standard treatment for patients with stage III colon cancer and deficient mismatch repair,” said study author Frank …
Leave a Comment Leave a Comment
